Biology
Biology News
Society of Interventional Radiology hosts oncology therapies Webinar, offers resources
| 11/6/2009 | FAIRFAX, Va.Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation. SIR is a national organization of physicians, scientists and allied health professionals dedicated to im... [Comments] |
AIBS publishes Darwin articles open access
| 11/6/2009 | To celebrate the 150th anniversary this month of the publication of On the Origin of Species, the American Institute of Biological Sciences (AIBS) is publishing open access two peer-reviewed articles about Charles Darwin and his historic insights into evolution. The two articles are by Kevin Padian of the University of California, Berkeley, and James T. Costa of Western Carolina University.... [Comments] |
Ants are friendly to some trees, but not others
| 11/6/2009 | Tree-dwelling ants generally live in harmony with their arboreal hosts. But new research suggests that when they run out of space in their trees of choice, the ants can get destructive to neighboring trees. The research, published in the November issue of the American Naturalist , is the first to document that ants bore into live trees, and it reopens a centuries-old debate on the relatio... [Comments] |
National Institutes of Health Secures Armory with Patent-Pending Technology
| 11/6/2009 | DETROIT, Nov. 6 Auburn Hills, MI-based Law Enforcement Intelligent Devices, LLC (LEID) will be installing its locker system and patent-pending Biometric Access Control System(TM) (BACS) at the U.S. Department of Health and Human Services' National Institutes of Health (NIH) based in Bethesda, MD. The locker system will support the NIH's entire police force that is responsi... [Comments] |
Monell Center joins with CAS to host Beijing meeting on taste and smell research
| 11/6/2009 | PHILADELPHIA (November 06, 2009) The Monell Center and the Chinese Academy of Sciences (CAS) are co-hosts of the Beijing International Meeting on Taste and Smell Research. Organized by Monell in collaboration with the CAS, the meeting will be the first international meeting on taste and smell to be held in China. Alan Leshner, Chief Executive Officer, American Association for the Advancem... [Comments] |
Biologists, educators recognize excellence in evolution education
| 11/5/2009 | The National Association of Biology Teachers (NABT) will recognize Leonard C. Yannielli, professor of biological sciences at Naugatuck Valley Community College (NVCC) in Waterbury, Connecticut, with the 2009 Evolution Education Award during the NABT annual professional development conference to be held 11-14 November 2009 in Denver, Colorado. The Evolution Education Award is cosponsored by... [Comments] |
New synthetic molecules trigger immune response to HIV and prostate cancer
| 11/5/2009 | New Haven, Conn.Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society , could lead to novel therapeutic approaches for these diseases. The molecules called "antibody-recruiting mol... [Comments] |
Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing
| 11/5/2009 | Kent State University has been awarded a training grant in the amount of $2,756,719 by the National Science Foundation under its Integrative Graduation Education and Research Training (IGERT) program. This is the first IGERT grant to be awarded to Kent State. The grant, which is funded under the American Recovery and Reinvestment Act of 2009, runs through 2014. The grant funds an IGERT pro... [Comments] |
Biology Products
Mouse Anti-Snail, a.a. 150-39 Antibody, Unconjugated from CHEMICON
Description:Snail, a.a. 150-39...Company:CHEMICON
Rat Anti-Mouse IgM Heavy Chain Monoclonal Antibody, Unconjugated, Clone LO-MM-3 from Cell Sciences
Description:Anti-Mouse IgM Heavy Chain, Clone LO-MM-3, Monoclonal Antibody...Company:Cell Sciences
Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc
Description:HOXC11 Antibody...Company:ProSci, Inc
Rabbit Anti-BAFF-R (CT) BR3 Polyclonal Antibody, Unconjugated from ProSci, Inc
Description:BAFF-R (CT) BR3 Affinity Purified Polyclonal Antibody...Company:ProSci, Inc
Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc
Description:HOXC11 Antibody...Company:ProSci, Inc
Biology Technology
| 11/7/2009 | CAMBRIDGE, Mass., Nov. 7, Research projects in the areas of mathematics and biochemistry scored top marks this evening, as Tim Kunisky of Livingston, NJ and the team of Benjamin Song and Quan (Jack) Chen of Audubon, PA received the highest honors at the Region Five Finals of the 2009 Siemens Competition in Math, Science & Technology, the nation's premier high school sci... [Comments] |
Microbix Biosystems Re-files Annual Results With OSC
| 11/6/2009 | TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (the "Company") announces today that it has re-filed the Form 52-109F1 Certification of Annual Filings of William Gastle, the Chief Executive Officer and James Long, the Chief Financial Officer (the "Officer's Certificates") dated January 12, 2009 in connection with the annual audited financial statements for the year ended... [Comments] |
Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
| 11/6/2009 | LYNBROOK, N.Y., Nov. 6 BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. "We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommend... [Comments] |
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
| 11/6/2009 | AURORA, Ontario, Nov. 6 Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading produ... [Comments] |
| 11/6/2009 | QUINCY, Mass., Nov. 6 Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myria... [Comments] |
(Date:11/4/2009)...mber 4, 2009 Childhood obesity in the United Stat...n one fourth of advertising on daytime and prime t...continuing questions about the role television pla...sue of the Journal of Nutrition Education and Beh...dren might be a large contributor to the problem. ...
(Date:11/4/2009)...atory that deciphered the DNA codes, or genomes, o...k, has joined The Genome 10K Project, an internati...NA sequences on 10,000 species of animals for cond...ly can not be achieved. , Participating in The G...in the Nov. 5, 2009 issue of the Journal of Hered...
(Date:11/4/2009)... Calif., Oct. 19 Spectros, develop...and imaging devices which shed light on life-threa...d exclusive distribution deals for both its T-Stat...ts covered include Australia, New Zealand, The Ne..., Italy, France, Spain, Portugal, Poland, Greece, ...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 1Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 2Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 3Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 4Injury and hazards in home health care nursing are a growing concern 59078 1Injury and hazards in home health care nursing are a growing concern 59078 2Injury and hazards in home health care nursing are a growing concern 59078 3NIH grant will boost electron microscopy at Brandeis 10290 1NIH grant will boost electron microscopy at Brandeis 10290 2...LLA, CA Ever since insects developed a taste for ...e limited resources to out-compete their neighbors... against hungry insects. Now, an international tea...al Studies and the Institute of Investigaciones Fi...EVA) has discovered how plants weigh the tradeoffs...
...NGHAM, Ala. The human immunodeficiency virus (HIV... any successful AIDS vaccine must keep pace with t...s, according to researchers at the University of A...xford in England. , A new study better describes ... different "escape mutations" that help keep the v...
...tists from Queen Mary, University of London have d...y be the key to beating a viral infection which is...ommunities of common frogs (Rana temporaria) are b...ated to be killing tens of thousands of frogs in t... surrounding lawn becomes strewn with dead frogs, ...
Other Biology News:Understanding natural crop defenses 2Understanding natural crop defenses 3HIV adapts to 'escape' immune response 2Frog's immune system is key in fight against killer virus 2IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham Biosciences
APO-BrdU TUNEL Assay Kit with Alexa Fluor 488 anti-BrdU from Molecular Probes (Invitrogen)
Flammable Chemical Cabinets, Justrite Model RL25762Y from South Coast Enterprises
IMAGEQUANT 300 IQTL from GE Healthcare, formerly Amersham Biosciences
Biology Products:IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham BiosciencesAPO-BrdU TUNEL Assay Kit with Alexa Fluor 488 anti-BrdU from Molecular Probes (Invitrogen)Flammable Chemical Cabinets, Justrite Model RL25762Y from South Coast EnterprisesIMAGEQUANT 300 IQTL from GE Healthcare, formerly Amersham Biosciences
(Date:11/5/2009)...wire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: K...or processing and storing adult stem cells, today ...010. ,, For the quarter ended September 30, 200...a 15 percent increase over revenues of $4.5 millio...d the key contributors to the growth in revenues i...
(Date:11/5/2009)...FirstCall/ -- Cepheid (Nasdaq: CPHD ) today annou...ollowing investor conferences, and invited investo... Credit Suisse Healthcare Conference, Phoenix, AZ,... a.m. Mountain Time, NASDAQ OMX 2... Tuesday, 1 December, 2009 at 10.45 a.m. Green...
(Date:11/5/2009)...SpineSmith Partners has signed an initial agreemen...old that mimics the structure of natural cancellou...l products by SpineSmith,s Research and Developmen...affold represents a significant advancement in tec...t for the delivery of adult stem cells for skeleta...
(Date:11/5/2009)...ngs a new look to Pro Repro , ...sional Reprographics, Orange County’s fastes...ent Brooke Sanders to the company. Brooke joins th...ition of Brooke to the company represents continue...raphics., , ,Brooke brings with her over five year...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2[0] ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line[0] Cepheid to Webcast Upcoming Financial Presentations[0] SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement[0] Professional Reprographics Hires Recent Cal Poly Grad to Join their Team
... Inc. today announced that it has been awarded a $...earch (SBIR) grant from the National Institute of ...ional Institutes of Health (NIH). The grant will ...gy and pharmacology studies of the company,s propr...s being developed as a potential treatment for gro...
...e sublingual lozenge) as the first sleep aid speci...e-night awakenings , , PT. RICHMOND, Calif., ...ely-held specialty pharmaceutical company, announc...e U.S. Food and Drug Administration (FDA) that the...olpidem tartrate sublingual lozenge) has been acce...
...Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) toda...P. (Celtic) has provided an update on XERECEPT(R)....related to XERECEPT to Celtic in,November 2005. NT...he,achievement of certain regulatory approvals, an... is also entitled to receive profit-sharing paymen...
Other Biology Technology:Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 3Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 4Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 5Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 2Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 3Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 4Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone ProductTranscept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |